29 November 2024,   02:47
more
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial

A new coronavirus vaccine has been shown to be 89.3% effective in large-scale UK trials, writes BBC.


The Novavax jab is the first to show it is effective against the new variant of the virus discovered in the UK, the BBC’s medical editor Fergus Walsh said.


The PM welcomed the “good news” and said the UK’s medicines regulator would now assess the vaccine.


The UK has secured 60 million doses of the jab, which will be made in Stockton-on-Tees.


The doses are expected to be delivered in the second half of this year, if approved for use by the Medicines and Healthcare Products Regulatory Agency, the government said.

MORE HEADLINES